Epigral to host Bellwether Capital for plant visit in Gujarat

0 min read | Published on 31 Aug 2026, 06:58 PM |Updated on 31 Aug 2026, 08:44 PM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Epigral Limited hosts Bellwether Capital for a plant visit
Engagement scheduled for September 3, 2026
Location is the manufacturing facility in Dahej, Gujarat
No unpublished price-sensitive information to be shared

*this image is generated using AI for illustrative purposes only.

Epigral Limited has scheduled an investor and analyst plant visit for September 3, 2026. The company will host representatives from Bellwether Capital at its manufacturing facility in Dahej, Gujarat.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Epigral informed the National Stock Exchange of India Limited and BSE Limited on August 31, 2026, regarding the upcoming engagement.

Visit Details

The plant visit is planned for Thursday, September 3, 2026. The location is the Dahej unit in Gujarat. The mode of interaction is an in-person plant visit.

Detail	Information
Investor/Analyst	Bellwether Capital
Date	September 3, 2026
Location	Dahej, Gujarat
Mode	Plant Visit

Regulatory Disclosures

Epigral stated that the schedule is subject to change due to exigencies on the part of the analyst, investor, or the company. The firm emphasized that no unpublished price-sensitive information will be shared or discussed during the visit.

Gaurang Trivedi, Company Secretary and Compliance Officer, signed the intimation filed with the exchanges.

Historical Stock Returns for Epigral

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.99%	-10.19%	-20.33%	+21.19%	-41.92%	+26.21%

Disclaimer: This article is AI-generated using data from LiveSquawk. ScanX is not liable for any inaccuracies.

What specific operational metrics or capacity expansion plans at the Dahej facility is Bellwether Capital likely focusing on during this visit?

How might insights from this engagement influence Epigral's valuation multiples in the near term compared to its peers?

Could this targeted investor outreach signal upcoming strategic initiatives, such as new product launches or M&A activity, for Epigral?

Epigral

View Company Insights

View All News

Epigral schedules one-on-one meeting with Incred Research on August 20

0 min read | Published on 18 Aug 2026, 07:14 PM |Updated on 18 Aug 2026, 08:23 PM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

Key Highlights

Epigral Limited has scheduled a one-on-one meeting with Incred Research Services Pvt. Ltd. on August 20, 2026, in Ahmedabad, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that no unpublished price sensitive information will be shared during the meeting. Relevant presentations have been made available on the company's website ahead of the interaction.

*this image is generated using AI for illustrative purposes only.

Epigral Limited has notified the stock exchanges of a one-on-one meeting with Incred Research Services Pvt. Ltd., scheduled for August 20, 2026, in Ahmedabad. The intimation was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that no unpublished price sensitive information will be shared or discussed in the meeting.

Meeting details

The key details of the scheduled interaction are as follows:

Parameter:	Details
Investor/Analyst:	Incred Research Services Pvt. Ltd.
Date:	August 20, 2026
Mode:	One-on-One Meeting
Location:	Ahmedabad

Presentation availability

Epigral noted that the latest Earnings Presentation and Corporate Presentation that may be discussed during the meeting have already been placed on the company's website. The schedule of the meeting is subject to change due to exigencies on the part of institutional investors or the company.

Historical Stock Returns for Epigral

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.99%	-10.19%	-20.33%	+21.19%	-41.92%	+26.21%

Disclaimer: This article is AI-generated using data from LiveSquawk. ScanX is not liable for any inaccuracies.

How might Incred Research's upcoming coverage or rating change following this one-on-one meeting impact Epigral's stock valuation?

What specific operational or financial metrics is Epigral likely to highlight to institutional investors to justify its current market position?

Could this engagement signal Epigral's intent to increase its visibility among domestic institutional investors ahead of any potential fundraising activities?

Epigral

View Company Insights

View All News